# Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

> **NCT01810588** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 270 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DEVICE:** CliniMACS® CD34 Reagent System
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** anti-thymocyte globulin (rabbit)
- **DRUG:** Rituximab
- **RADIATION:** Total Body Irradiation
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01810588
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-10-16
- **Primary completion:** 2023-08-09
- **Final completion:** 2028-04
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01810588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01810588, "Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT01810588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*